Patents Assigned to SmithKline Beecham Corporation
-
Publication number: 20100227856Abstract: This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted piperidines, according to Formula I Specifically, the invention is directed to compounds according to Formula I wherein R1 is optionally substituted aryl; X is CH2, S, or SO2; and n=1 or 2.Type: ApplicationFiled: February 16, 2007Publication date: September 9, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventor: Robert W. Marquis, JR.
-
Publication number: 20100210706Abstract: The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a combination thereof, wherein R1, R2, and X are as defined herein. Compounds of the present invention are useful as progesterone receptor modulators.Type: ApplicationFiled: August 7, 2007Publication date: August 19, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: David G. Washburn, Scott Kevin Thompson, Marlys Hammond, James S. Frazee, Tram H. Hoang, Latisha C. Johnson
-
Publication number: 20100196310Abstract: The present invention relates generally to the use of human IL-18 combinations in the treatment of various forms of solid tumors and lymphomas. In particular, the present invention relates to: (1) combinations of human IL-18 with monoclonal antibodies against antigens that are expressed on the surface of cancer cells; and (2) combinations of human IL-18 with chemotherapeutic agents.Type: ApplicationFiled: March 20, 2008Publication date: August 5, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Zdenka Haskova, Zdenka Ludmila Jonak, Stephen H. Trulli, Margaret N. Whitacre
-
Publication number: 20100168122Abstract: The present invention relates to compounds of formula (I) which are xanthine derivatives, processes for manufacture of said derivatives, pharmaceutical formulations containing these compounds and the use of the compounds in therapy, for example, in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficialType: ApplicationFiled: August 8, 2006Publication date: July 1, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Richard Jonathan Daniel Hatley, Andrew McMurtrie Mason, Ivan Leo Pinto
-
Publication number: 20100168100Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.Type: ApplicationFiled: May 16, 2008Publication date: July 1, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Nicholas D. Adams, Amita M. Chaudhari
-
Publication number: 20100160209Abstract: The invention provides for a cell permeable peptide conjugated to an insulin compound for improved cell penetration of the insulin moiety. The composition may be delivered by intravenous, intramuscular, subcutaneous, intranasal, oral inhalation, intrarectal, intravaginal or intraperitoneal means for the treatment, including prophylaxis of Type I, Type II diabetes, prediabetes and/or metabolic syndrome.Type: ApplicationFiled: May 10, 2007Publication date: June 24, 2010Applicant: SmithKline Beecham CorporationInventors: Dany Doucet, Mickey Lee Wells
-
Publication number: 20100120799Abstract: Compounds of formula (I): wherein R1 is C1-8alkylamino, C1-8alkoxy, C3-7cycloalkylC1-6alkylamino, C3-7cycloalkylC1-6alkoxy, C1-3alkoxyC2-3alkoxy, or Hetb-C1-3alkoxy; Hetb is a 5- or 6-membered saturated aliphatic heterocycle containing one oxygen atom; R2 is —(CH2)n-Het; n is an integer having a value of 1 to 4; Het is a 5- or 6-membered saturated aliphatic heterocycle containing one oxygen heteroatom, which heterocycle may be substituted by one or two C1-4alkyl groups, and salts and solvates thereof, are inducers of human interferon and may be useful in the treatment of various disorders in particular infectious diseases, cancer, and allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, and as vaccine adjuvants.Type: ApplicationFiled: February 15, 2008Publication date: May 13, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Linos Lazarides, Stephen Allan Smith, Richard Stocker, Colin Jack Theobald
-
Publication number: 20100120775Abstract: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.Type: ApplicationFiled: October 23, 2007Publication date: May 13, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Jonathan York Bass, III, David Norman Deaton, Justin Caravella, Robert Blount McFadyen, Frank Navas, III, Paul Kenneth Spearing
-
Patent number: 7713982Abstract: The present invention relates to a therapeutically active xanthine derivative compound of formula (I): corresponding pharmaceutical formulations containing, manufacture processes for, methods or uses of such compounds in therapy, in particular for treatment of diseases where under-activation of the HM74A receptor contributes to such diseases or where activation of the HM74A receptor will be beneficial.Type: GrantFiled: February 10, 2005Date of Patent: May 11, 2010Assignee: Smithkline Beecham CorporationInventor: Ivan Leo Pinto
-
Publication number: 20100105712Abstract: Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.Type: ApplicationFiled: October 30, 2009Publication date: April 29, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Amogh Boloor, Mui Cheung, Philip Anthony Harris, Kevin Hinkle, Jeffery Alan Stafford, James Marvin Veal
-
Publication number: 20100105749Abstract: The present invention provides compounds of the formulae (I) and (II), and derivatives thereof, for the treatment of cardiovascular conditionsType: ApplicationFiled: January 30, 2008Publication date: April 29, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Jon Loren Collins, Jodi Maglich Goodwin, Millard Hurst Lambert, III
-
Publication number: 20100086554Abstract: The present invention relates to methods of treating nasal polyposis, in a human, comprising the step of administering to said human in need thereof an effective amount of a composition comprising at least one anti-11-5 antibody wherein said antibody comprises a heavy chain and a light chain.Type: ApplicationFiled: April 30, 2008Publication date: April 8, 2010Applicant: SmithKline Beecham CorporationInventor: Claus Bachert
-
Publication number: 20100086547Abstract: The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, methods are provided for reducing eosinophils in a human in need thereof, which method comprises administering to said human a composition comprising at least one anti-IL-5 antibody, wherein at least one anti-IL-5 antibody provides a mean maximum plasma concentration of said anti-IL-5 antibody of at least about 1.03±0.21 ?g/mL, an Area Under the Curve value of at least about 15.5±2.7 ?g/day/mL and a serum half-life of about 16.2±2.1 days to about 21.7±2.8 days.Type: ApplicationFiled: April 30, 2008Publication date: April 8, 2010Applicant: SmithKline Beecham CorporationInventors: Bela Rajiv Patel, Deborah Smith, Debra J. Tompson, Parnian Zia-Amirhosseini
-
Publication number: 20100081792Abstract: The invention provides a dual-specific ligand comprising a first and second single variable domain, each having binding specificity for a antigenic target. The invention also provides for a single variable domain monomer ligand that specifically binds to an antigenic target.Type: ApplicationFiled: October 31, 2007Publication date: April 1, 2010Applicant: SmithKline Beecham CorporationInventors: Steven Grant, Amrik Basran, Olga Ignatovich, Rudolph Maria T. De Wildt, Philip Jones, Neil Brewis, Ben Woolven, Elena De Angelis, Lucy J. Holt, Greg Winter, Ian Tomlinson, Kevin Moulder
-
Publication number: 20100075995Abstract: Compounds of formula (I): wherein R1 is C1-6alkylamino, C1-6alkoxy, or C3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.Type: ApplicationFiled: August 7, 2009Publication date: March 25, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Keith Biggadike, Diane Mary Coe, Xiao Qing Lewell, Charlotte Jane Mitchell, Stephen Allan Smith, Naimisha Trivedi
-
Publication number: 20100056760Abstract: Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents.Type: ApplicationFiled: May 29, 2009Publication date: March 4, 2010Applicant: SmithKline Beecham CorporationInventors: Julie A. ABRAHAMSON, Connie L. Erickson-Miller, Kristine K. Kikly, Bruce Bochner, Robert Schleimer, T. Esra Nutku
-
Publication number: 20100050770Abstract: An apparatus comprises a main body member; and a transducer in communication with the main body member, the transducer adapted to receive an acceleration force imparted to the main body member. A method for assessing acceleration forces imparted to an apparatus comprises a main body member and transducer in communication with the main body member, the transducer adapted to receive the external acceleration force imparted to the main body member, wherein the transducer converts the acceleration forces to electrical signals and the acceleration forces are accessed.Type: ApplicationFiled: January 6, 2006Publication date: March 4, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Lee A. Barger, Donald D. Munn
-
Patent number: 7668662Abstract: A patient-specific optimally effective radiation dose for administration of a radiopharmaceutical to a patient for treatment of a disease may be established by basing the calculation of the appropriate therapeutic dose on factors such as the desired total body dose, the maximum tolerated dose, the typical clearance profile of the radiopharmaceutical, the patient's mass or maximum effective mass, and the patient-specific residence time of the radiopharmaceutical or an analog in the whole body of the patient. The use of the method allows for treatment of a patient with an appropriate dose which is maximally effective against the disease yet minimally toxic. The determination of a patient-specific therapeutic dose may be assisted by the use of a software program set to the particular parameters of the radiopharmaceutical.Type: GrantFiled: August 10, 2005Date of Patent: February 23, 2010Assignees: The Regents of the University of Michigan, Smithkline Beecham CorporationInventors: Stewart M. Kroll, Jeffry A. Siegal, Richard L. Wahl, Kenneth R. Zasadny
-
Publication number: 20100029782Abstract: Novel calcilytic compounds of Formula (I), pharmaceutical compositions, methods of synthesis, and methods of using them are provided.Type: ApplicationFiled: December 18, 2007Publication date: February 4, 2010Applicant: Smithkline Beecham CorporationInventors: Robert W. Marquis, JR., Joshi M. Ramanjulu, Robert Trout
-
Patent number: D609094Type: GrantFiled: September 9, 2008Date of Patent: February 2, 2010Assignee: SmithKline Beecham CorporationInventor: Angie Yonju Kim